Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Tixagevimab and cilgavimab use in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder during anti-CD20 treatment: A single-center experienceJ. Neuroimmunol. 2023 Sep 13;383(xx)578199, S Gelibter, F Pirro, L Saraceno, E Susani, MC Moioli, M Puoti, EC Agostoni, A Protti
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.